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Emerging infectious disease outbreaks and bioterror-
ism attacks warrant urgent public health and medical
responses. Response plans for these events may include
use of medications and vaccines for which the effects on
pregnant women and fetuses are unknown. Healthcare
providers must be able to discuss the benefits and risks of
these interventions with their pregnant patients. Recent
experiences with outbreaks of severe acute respiratory
syndrome, monkeypox, and anthrax, as well as response
planning for bioterrorism and pandemic influenza, illustrate
the challenges of making recommendations about treat-
ment and prophylaxis for pregnant women. Understanding
the physiology of pregnancy, the factors that influence the
teratogenic potential of medications and vaccines, and the
infection control measures that may stop an outbreak will
aid planners in making recommendations for care of preg-
nant women during large-scale infectious disease emer-
gencies.
A
primary goal of public health response to emerging
infections and bioterrorism attacks is to limit illness
and death by providing the safest and most effective med-
ical prophylaxis and treatment measures (medical coun-
termeasures) in a timely manner to persons at greatest
risk. Information on the effectiveness and safety of some
medical countermeasures is limited for the general popu-
lation, and even less information is available for pregnant
women (1). Physiologic changes during pregnancy may
change the safety profile and efficacy of medications and
vaccines for pregnant women. The potential effect of
many of these measures on the fetus is unknown. These
factors could influence a clinician’s willingness to pre-
scribe and a woman’s decision to accept potentially life-
saving treatments.
The circumstances under which exposure to medica-
tions or vaccines during pregnancy occurs must be taken
into account. For example, when a pregnant woman has a
serious acute infection, such as severe acute respiratory
syndrome (SARS), anthrax, or a pandemic strain of
influenza, appropriate timely treatment must be provided
to preserve her health. When multiple therapeutic interven-
tions of similar efficacy are available, consideration can be
given to choosing the therapy that will best safeguard
maternal health and the well-being of the embryo or fetus.
In contrast, when a pregnant woman has been exposed to a
serious infection but is not acutely ill, the choice of
whether to provide prophylaxis or empirical treatment
depends on several factors including the nature and cer-
tainty of the exposure, likelihood and potential severity of
her infection, and gestational age at which exposure
occurred. Inadvertent exposure to a medication or vaccine
also may occur during pregnancy. An estimated half of
pregnancies in the United States are unplanned (2); thus, a
woman infected with or exposed to a serious acute infec-
tion might receive emergency prophylactic or treatment
measures during the early weeks of gestation before a
pregnancy is recognized. In this situation, opportunity to
weigh the risks and benefits to a pregnancy before expo-
sure to the medication or vaccine is missed; instead, con-
sideration must focus on any effects these measures may
have had on the fetus.
Special Physiologic Features of Pregnancy
Physiologic changes in maternal organ systems during
pregnancy, beginning in the first trimester and peaking in
the second, can have effects on the pharmacokinetics of
Prophylaxis and Treatment of
Pregnant Women for Emerging
Infections and Bioterrorism
Emergencies 
Joanne Cono,* Janet D. Cragan,* Denise J. Jamieson,* and Sonja A. Rasmussen*
*Centers for Disease Control and Prevention, Atlanta, Georgia,
USAsome drugs. A drug’s pharmacokinetics (i.e., attainment
and maintenance of the appropriate drug serum concentra-
tion) are affected by 4 major factors: absorption, distribu-
tion, metabolism, and elimination (3). Because physiologic
changes are evolving continuously during pregnancy,
pharmacokinetic information must be interpreted with
regard to gestational age (4).
Changes in the maternal gastrointestinal and cardiovas-
cular systems affect drug absorption. Delayed gastric emp-
tying and decreased gastrointestinal motility, largely due to
elevated levels of progesterone that relax smooth muscle,
influence absorption of drugs taken orally. In addition, a
decrease in gastric acid secretion results in higher gastric
pH, which affects absorption of weak acids and bases
(4,5). Increased blood flow to the stomach and small intes-
tine, resulting from changes in the cardiovascular system
(most notably, a 30%–50% increase in cardiac output) (4),
increases absorption of drugs taken orally (3). Elevated
blood flow also increases the absorption of drugs adminis-
tered intramuscularly. However, late in pregnancy
decreased blood flow to the lower extremities may result in
decreased absorption in these areas (6).
Plasma volume increases by 30%–50% during preg-
nancy to meet the increased requirements of uterine-pla-
cental circulation. This increase results in a higher volume
of distribution for most drugs. As the plasma volume
expands, the volumes of extracellular fluid and total body
water also increase. Total body weight and body fat
increase throughout pregnancy, resulting in a larger vol-
ume of distribution, particularly for fat-soluble drugs (3).
As plasma albumin concentrations decrease, so do concen-
trations of proteins available for binding, resulting in high-
er circulating amounts of free, unbound drug (5). However,
unbound drugs may be more easily cleared by the kidney
and liver, which may offset the effect of the increased vol-
ume of distribution (7).
During pregnancy, enzyme activity in the liver, a major
site for drug metabolism, changes considerably. Activity of
certain liver cytochromes (e.g., CYP3A4, CYP2D6) is
increased during pregnancy. However, activity of
CYP1A2, the enzyme responsible for metabolism of
approximately half of all pharmacologic agents, is
decreased. Increases in estrogen and progesterone during
pregnancy also alter hepatic enzyme activity (3,4).
Several factors affect drug elimination during pregnan-
cy. Changes in kidney function parallel the changes in car-
diac function, with a 60%–80% increase in renal blood
flow and a 50% increase in the glomerular filtration rate.
Renal secretion and reabsorption increase by ≈20% (5).
Drug elimination also occurs through respiration, which
becomes a more important route during pregnancy because
of changes in pulmonary function, including increased
tidal volume, minute volume, and respiratory rate (3).
Although these physiologic changes during pregnancy
can have varied and substantial effects on drug pharmaco-
kinetics, data about their effects are limited. No evidence-
based guidelines exist for how drug dosing should be
altered during pregnancy (1). Thus, pregnant women are
usually given medication doses and schedules identical to
those of nonpregnant adults, despite evidence that effec-
tive therapeutic levels and toxicity may be altered by preg-
nancy (4).
Vaccine efficacy during pregnancy is another area that
merits further investigation. During pregnancy, the mater-
nal immune system undergoes extensive changes.
Although these changes are not well understood, a shift
away from cell-mediated immunity and toward humoral
immunity appears to occur. How these immune alterations
affect maternal response to vaccination during pregnancy
is unknown (8). However, limited data on several vaccines
(e.g., hepatitis B, influenza, group B Streptococcus) sug-
gest that the immune response of pregnant women to these
vaccines is similar to that of nonpregnant women (9).
Teratogenic Potential of Medications 
and Vaccines
Whether use of a medication or vaccine is harmful to the
embryo or fetus depends on multiple factors, including the
nature of the agent (e.g., live versus killed vaccine), its dose
and route of administration, timing of use during gestation,
concomitant use of other agents, nature of the infection
being treated or prevented, and genetic susceptibility of the
pregnant woman and of the embryo or fetus. Potential
adverse effects of an exposure on the embryo or fetus
include spontaneous pregnancy loss, structural malforma-
tions, intrauterine growth restriction, preterm delivery,
hearing loss, and neurobehavioral abnormalities, among
others. Timing of exposure during gestation is particularly
critical. Organogenesis, the period of organ formation,
extends from 15 to 60 days after fertilization (≈4–11 weeks
after the start of the last menstrual period) (10). Before
organogenesis, harmful exposures are most likely to result
in spontaneous pregnancy loss, although some embryos
that survive can be adversely affected (11). After this time,
structural abnormalities are less likely to occur, although
damage to a normally formed organ is still possible (12). In
addition, some teratogenic medications have a narrow win-
dow of exposure when their use results in malformations.
For example, thalidomide is believed to produce malforma-
tions only when used 34–50 days after the beginning of the
last menstrual period (13). In contrast, adverse outcomes
such as growth retardation and functional abnormalities can
result from later exposures. Angiotensin-converting
enzyme inhibitors have been associated with impaired renal
function in the newborn when used to treat maternal hyper-
tension during the latter half of pregnancy (13).
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tions and vaccines are usually assessed in animal studies
before these products are licensed for human use. Efficacy
in humans is evaluated in premarketing clinical trials.
However, because of ethical concerns about exposing an
embryo or fetus to an agent with unknown effects, repro-
ductive studies are not performed in humans before licen-
sure, and pregnant women have traditionally been
excluded from clinical trials of efficacy (14). Although
animal studies can be useful in evaluating an agent’s
potential for adverse reproductive effects, they are not
always predictive of the effects in humans.
For these reasons, information about the effects of med-
ications and vaccines during pregnancy is usually obtained
from data collected after these agents are in use in the pop-
ulation. These data take the form of adverse event reports,
case series, prospective exposure registries, and cohort and
case-control studies, each of which has its own method-
ologic strengths and limitations (15). Conclusive informa-
tion can be difficult to obtain from these studies because of
low levels of use of individual medications or vaccines in
the population outside of an emergency setting and the dif-
ficulty of separating reproductive effects of the medication
or vaccine from those of the underlying infection or other
genetic and environmental factors. A2001 review of avail-
able information about medications approved by the US
Food and Drug Administration (FDA) from 1980 through
2000 concluded that insufficient information existed to
assess the teratogenic potential of >90% of these drugs
(16).
In 1979, to help healthcare providers assess potential
risks and benefits of medications during pregnancy, FDA
developed a use-in-pregnancy rating system (21 CFR
201.57). This system labels drugs on the basis of assess-
ment of their relative risk to the fetus and their potential
benefit to the mother (17). Ranging from category A
through X (Table 1), this scale uses available data from
animal reproductive and human studies. This rating system
is used widely by clinicians in the United States, but it has
several shortcomings. These include the fact that medica-
tions in the same letter category may have different mag-
nitudes of fetal risk, most medications are rated category C
(i.e., insufficient information is available to assess their
potential risk and benefit during pregnancy), and the rating
is not routinely updated when new information becomes
available (18). In addition, this rating system does not
address the effects of gestational timing of exposure or of
physiologic changes that occur during pregnancy (18,19).
FDA recognizes these limitations and is working to
improve communication about the risks and safety of med-
ication use during pregnancy (20).
Use of Medical Countermeasures in Prophylaxis
and Treatment during Emerging Infection and
Bioterrorism Emergencies
Limited information about the effects of medications
and vaccines during pregnancy can pose a dilemma for
women and healthcare providers when making decisions
about their use. Pregnant women may be reluctant to
receive, or healthcare providers may be reluctant to pre-
scribe, needed medications or vaccines because of fear of
harming the fetus. However, if a pregnant woman has a
serious acute infection or has been exposed to a potential-
ly life-threatening infection, treatment or prophylaxis can
be lifesaving for both mother and fetus. Physicians and
women often overestimate the risk to the fetus of medica-
tion use during pregnancy (21). As a result, needed inter-
ventions may be withheld or pregnancies perceived to be
at risk may be terminated. Decisions about the treatment or
prophylaxis of emerging infections must take into account
the effect on the mother’s health and the potential risks for
the embryo or fetus.
In preparation for potential bioterrorism emergencies,
the US government has stockpiled medications and vac-
cines, most of which are rated by FDA as 1 of the cate-
gories B through X, which indicates that they could pose a
risk to the unborn fetus or that insufficient information
exists to evaluate their potential fetal risk (Table 2). Some
of these products (e.g., ciprofloxacin, gentamicin, and dox-
cycline) are commonly used in routine healthcare, but oth-
ers (e.g., smallpox and anthrax vaccines) are reserved for
emergency preparedness and response activities and for
deployed military personnel.
Some emergency response medications and vaccines
fall outside of the FDA labeling system because they are
not licensed by FDA. Some are newly developed and still
in prelicensure clinical trials; others are no longer licensed
and predate the classification system. In these instances,
the Centers for Disease Control and Prevention (CDC)
holds Investigational New Drug protocols, approved by
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in emergency situations. These protocols include extensive
educational materials for potential recipients about the
risks and benefits of treatment and include special consid-
erations for pregnant women.
Although limiting fetal exposure to treatments that may
pose unknown risks is optimal, protecting the life of the
mother is key in protecting the fetus. In an emergency set-
ting with a high risk for life-threatening exposure to an
infectious pathogen, recommendations likely will call for
the use of vaccination and prophylactic medications, when
they are available, for pregnant women, despite unknown
risks to the fetus. Other measures that can protect persons
who are unable or choose not to receive vaccination or pro-
phylactic medications include limiting exposure to persons
who may be infectious, avoiding public gatherings, and
restricting travel to affected areas.
Issues in Treatment and Prophylaxis of
Emerging Infections and Bioterrorism Attacks
In recent years, the public health and medical commu-
nities have faced several emerging infectious disease out-
breaks, including SARS and monkeypox, and much
consideration has been given to preparation for a future
influenza pandemic. In addition, experience with bioter-
rorism attacks (anthrax) and emergency response pre-
paredness (smallpox vaccination) has been gained. These
events required careful consideration of recommendations
for the care of pregnant women.
The SARS outbreak of 2003, caused by a newly identi-
fied coronavirus, affected >8,000 persons worldwide (22).
Reports suggest that the clinical course and outcomes of
SARS might be more severe for pregnant than for non-
pregnant women (23). Identifying appropriate treatment
modalities during the SARS outbreak was challenging,
given the lack of information about the newly identified
disease. Ribavirin was initially chosen because of its broad
antiviral spectrum. Corticosteroids were used in an attempt
to limit the tissue damage caused by the inflammatory
response (24). However, issues regarding the teratogenici-
ty of these medications have been raised, further compli-
cating decisions about their use during pregnancy. Some
animal studies have suggested that ribavirin is teratogenic,
but limited experience is available regarding its effects on
human pregnancies (25). Animal studies and some human
studies have demonstrated an increased risk for birth
defects when corticosteroids are used during pregnancy
(26). In spite of this information, all but 1 of the 12 preg-
nant women with SARS reported from Hong Kong Special
Administrative Region, People’s Republic of China
Special Administrative Region, People’s Republic of
China received ribavirin and corticosteroid treatment (22),
probably because their illness was life-threatening. On the
basis of more recent data, the efficacy of ribavirin and cor-
ticosteroids in the treatment of patients with SARS has
been questioned (24). Other medications, such as interfer-
ons, have been proposed for use in future SARS outbreaks,
but use of these medications in pregnant women may also
be of concern.
In June 2003, the first outbreak of monkeypox in the
Western Hemisphere occurred in the United States (27).
Because of the high death rate associated with monkeypox
on the African continent (28) and lack of experience with
monkeypox in the United States, CDC recommended
smallpox (vaccinia) vaccination (≈85% effective against
monkeypox) (29). The outbreak was traced to importation
of infected rodents that infected pet prairie dogs and other
small mammals kept as pets.  Smallpox vaccination during
pregnancy poses a low risk for fetal vaccinia, which can
lead to preterm birth, and fetal and neonatal death (30,31).
However, women who were exposed were advised to
receive the smallpox vaccine regardless of their pregnancy
status (32), given the life-threatening risk associated with
monkeypox infection.
Planning for a future influenza pandemic must include
specific considerations for pregnant women (33). Because
pregnancy has been shown to increase the risk for influen-
za-associated complications (34), pregnant women are
considered a high-risk group and are recommended to
receive influenza vaccination during interpandemic years
(35). This vaccine is inactivated and is considered safe for
pregnant women. It is reformulated each year to include
the anticipated viral strains of the upcoming influenza
season.
Pregnant women also should be considered at increased
risk from influenza infection in the event of pandemic
influenza. Vaccination of pregnant women not only bene-
fits the woman herself but also indirectly confers immuni-
ty to her infant, which can last the first 6 months of life
when vaccination is not approved for children (36). During
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able or in limited supply. In such a situation, chemopro-
phylaxis will be an important option for pregnant women.
Unfortunately, no information is available regarding the
effects on the fetus of neuraminidase inhibitors
(oseltamivir and zanamvir), the medications likely to be
useful in an H5N1 pandemic (36). Thus, weighing the risks
associated with infectious exposure in a pregnant woman
and risks associated with medication exposure to her
unborn child is difficult.
The anthrax attacks of 2001 prompted the first, large-
scale recommendations for use of prophylactic medica-
tions in response to bioterrorism. The recommended
medication for initial antimicrobial drug prophylaxis of
asymptomatic exposed adults was ciprofloxacin, with
doxycycline and amoxicillin as alternative therapies if the
strain was susceptible (37). Because of an observed asso-
ciation between fluoroquinolones and joint and cartilage
toxicity in juvenile animals (38), ciprofloxacin is general-
ly not recommended during pregnancy if efficacious alter-
natives are available. Although information on the safety
of ciprofloxacin in pregnant women was lacking, the
available limited information suggested that its use during
pregnancy was unlikely to be associated with a high risk
for structural birth defects. In addition, maternal exposure
to tetracyclines, which include doxycyline, carries the
known risks of staining the primary teeth, concern about
bone growth and abnormal tooth enamel in the fetus (39),
and rare instances of hepatic necrosis in pregnant women.
Although penicillins are considered safe during pregnan-
cy, the fact that Bacillus anthracis strains may have peni-
cillinase activity led to the recommendation that
amoxicillin be used for prophylaxis only if the specific
strain was shown to be penicillin sensitive. On the basis of
these considerations, CDC recommended that
ciprofloxacin be the antimicrobial drug of choice for ini-
tial prophylactic therapy of asymptomatic pregnant
women exposed to B. anthracis during the 2001 anthrax
attacks (40). The American College of Obstetricians and
Gynecologists Committee on Obstetric Practice endorsed
these recommendations and emphasized that prophylaxis
be limited to women exposed to a confirmed environmen-
tal contamination or a high-risk source, as determined by
local public health officials (41).
In 2003, the United States embarked on an effort to vac-
cinate public health and medical bioterrorism response
teams against smallpox. In the absence of circulating
smallpox virus, vaccination in pregnant women or women
who desire to become pregnant within 28 days of the vac-
cination is contraindicated because of the risk for fetal vac-
cinia (30). However, after an intentional attack, pregnancy
should not be considered an absolute contraindication to
vaccination (30). In the event of exposure or high risk for
exposure to smallpox, pregnant women are advised to
receive the vaccine because the risk for death and serious
illness from smallpox (particularly during pregnancy) out-
weighs the risk for fetal vaccinia.
Despite the recommendations that pregnant women
avoid vaccination, several pregnant women were inadver-
tently vaccinated during the smallpox vaccination cam-
paign and were encouraged to enroll in the National
Smallpox Vaccine in Pregnancy Registry (42). Preliminary
results from the registry suggest that the rates of pregnan-
cy loss, preterm birth, and birth defects among infants born
to vaccinated women did not increase, but evaluation is
ongoing. Pregnancy registries such as this and the
Department of Defense Birth and Infant Health Registry
(43) should be considered whenever emergency response
activities invoke the use of medications or vaccines with
unknown effects on pregnant women and fetuses.
These examples demonstrate some of the challenges
faced by pregnant women and their healthcare providers
when considering prophylaxis and treatment in response to
emerging infections or bioterrorism attacks. In most
instances, information on the effects of the medication or
vaccine on the fetus is limited. Decisions regarding appro-
priate prophylaxis and treatment of pregnant women must
take into account the risks associated with specific medica-
tions or vaccines versus the risk for illness and death from
a possible infectious exposure.
Conclusions
Developing recommendations for prophylaxis and
treatment of pregnant women infected with emerging and
bioterrorism pathogens can be especially difficult. Data on
the effects of some emergency response countermeasure
treatments on pregnant women and fetuses are limited.
Emergency response planners should include recommen-
dations for pregnant women in pre-event response plans,
rather than creating them during an emergency. Clinicians
should become familiar with pregnancy-related recom-
mendations for prophylaxis and treatment of persons with
emerging and bioterrorism pathogens so that they are pre-
pared to discuss risks and benefits of recommended treat-
ments with their pregnant patients. In an emergency
response setting, pregnant women should be encouraged to
consider their own health and safety and the effect of
potential ill health on their pregnancy, should be offered
prenatal evaluation for fetal abnormalities if desired, and
should be encouraged to enroll in pregnancy registries
when applicable. Long-term goals should include evalua-
tion of the effects of emergency response treatments for
the pregnant woman and fetus, and research and develop-
ment of safer and effective medications when warranted.
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